Search

Displaying results 2621 - 2630 of 4691 in total
  1. Drug

    Brentuximab vedotin

    go.drugbank.com/drugs/DB08870
    ApprovedInvestigational

    This demonstrates meaningful progress in treatment for patients affected by this disease.[L1739] … [L1737] Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse

  2. Drug

    Mycophenolic acid

    go.drugbank.com/drugs/DB01024
    ApprovedInvestigational

    [A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until

  3. Drug

    Secobarbital

    go.drugbank.com/drugs/DB00418
    ApprovedVet approved

    Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties.

  4. Drug

    Aluminum oxide

    go.drugbank.com/drugs/DB11342
    ApprovedWithdrawn

    It is considered an indirect additive used in food contact substances by the FDA.

  5. Drug

    Calfactant

    go.drugbank.com/drugs/DB06415
    ApprovedInvestigational

    Calfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. It is an off-white suspension of an extract of natural surfactant from calf lungs suspended in 0.9% saline. Each milliliter of calfactant con...

  6. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. I...

  7. Drug

    Polatuzumab vedotin

    go.drugbank.com/drugs/DB12240
    ApprovedInvestigational

    [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141]

  8. Drug

    Oprelvekin

    go.drugbank.com/drugs/DB00038
    ApprovedInvestigationalWithdrawn

    Oprelvekin works by stimulating megakaryocytopoiesis and thrombopoiesis. … Oprelvekin, the active ingredient in Neumega®, is recombinant Interleukin-11 (IL-11), which is produced in Escherichia coli (E. coli) by recombinant DNA technology.

  9. Drug

    Vevorisertib

    go.drugbank.com/drugs/DB21481
    Investigational

    Vevorisertib is under investigation in clinical trial NCT02761694 (Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK

  10. Drug

    Nabiximols

    go.drugbank.com/drugs/DB14011
    Investigational

    While cannabis in its natural plant form is currently used "off-label" for the management of many medical conditions, THC is currently commercially available in synthetic form as [DB00486], as purified … The negative allosteric modulatory effects of CBD are therapeutically important as direct agonists are limited by their psychomimetic effects while direct antagonists are limited by their depressant effects